HUMAN LYMPHOID TISSUE INDUCER (LTi) CELL COMPOSITIONS AND METHODS OF USE
AssigneeLa Jolla Institute for Allergy and Immunology
InventorsCarl F. Ware, Vasileios Bekiaris
Life of this patent
Estimating the term…
Abstract
The invention provides human lymphoid tissue inducer (LTi) cells, methods of producing human lymphoid tissue inducer (LTi) cells, and methods of using human lymphoid tissue inducer (LTi) cells. Such methods include treatment of a subject that would benefit from human lymphoid tissue inducer (LTi) cells, for example, an immunocompromised or immunosuppressed subject.
Claims35
Isolated or purified human lymphoid tissue inducer (LTi) cells, wherein the LTi cells are characterized by expression of CD4, interleukin (IL)-7 receptor alpha, LTalpha, LTbeta, CD30 ligand, CC chemokine receptor 7 (CCR7), CD45, and Integrin β7 protein or mRNA.
A culture of human lymphoid tissue inducer (LTi) cells comprising a growth or storage medium, wherein the LTi cells are characterized by expression of CD4, interleukin (IL)-7 receptor alpha, LTalpha, LTbeta, CD30 ligand, CCR7, CD45, and Integrin β7 protein or mRNA.
A method of producing human lymphoid tissue inducer (LTi) cells, comprising
- a) removing or depleting cells expressing CD3 and CD19 from blood cells of a human donor thereby producing a cell population depleted of cells expressing CD3 and CD19;
- b) removing or depleting cells expressing CD41 and CD14 from the cell population thereby producing a cell population depleted of cells expressing CD41 and CD14;
- c) contacting the cell population depleted of cells expressing CD3, CD19, CD41 and CD14 with IL-7;
- d) co-culturing the cell population with human embryonic kidney-293T (HEK-293T, ATCC CRL-11268), NHDF (normal human dermal fibroblasts) or HT-29 (colonic epithelial tumor cell line, ATCC HTB-38) cells, or a human embryonic kidney-293T (HEK-293T, ATCC CRL-11268), NHDF (normal human dermal fibroblasts) or HT-29 (colonic epithelial tumor cell line, ATCC HTB-38) cell conditioned medium;
- and
- e) selecting cells from the cell population produced by steps a), b) and c) that express one or more of CD4, interleukin (IL)-7 receptor alpha, LTalpha, LTbeta, CD30 ligand, CCR7, CD45, and Integrin β7 protein or mRNA, thereby producing a population of human lymphoid tissue inducer (LTi) cells.
Dependencies are inferred from the claim text.